J. Llorca, and M. Delgado-Rodríguez. Medical science monitor : international medical journal of experimental and clinical research, 8 (10):
MT193-7(October 2002)3579<m:linebreak></m:linebreak>Risc atribuïble.
E. Schechtman. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 5 (5):
431-6(2002)Tamaño del efecto; Anàlisi de dades.
A. Barratt, P. Wyer, R. Hatala, T. McGinn, A. Dans, S. Keitz, V. Moyer, and G. For. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 171 (4):
353-8(August 2004)3595<m:linebreak></m:linebreak>A companion version of this article directed at teachers of evidence-based medicine http://www.cmaj.ca/cgi/data/171/4/353/DC1/1 - * An interactive version of this article as well as other tools and resources can be found at http://www.ebmtips.net/risk001.asp.;<m:linebreak></m:linebreak>Mesures d'associació.
C. West, and D. Dupras. Vaccine, 31 (12):
1550-2(March 2013)CI: Copyright (c) 2012; JID: 8406899; 2012/08/14 received; 2012/11/14 revised; 2012/11/28 accepted; 2012/12/11 aheadofprint; ppublish;<br/><br/>Critical appraisal; Interpretació de resultats; Errors; Risc relatiu vs absolut<br/><br/>Bona Figura de risc relatiu vs absolut.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
G. Siontis, and J. Ioannidis. International journal of epidemiology, 40 (5):
1292-307(October 2011)6416<m:linebreak></m:linebreak>JID: 7802871; 2011/07/06 aheadofprint; ppublish;<m:linebreak></m:linebreak>Tamaño del efecto; Interpretació de resultats.
H. Kim. Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (2 Pt 1):
559-65(January 2007)4698<m:linebreak></m:linebreak>LR: 20071203; GR: AI 029530/AI/NIAID NIH HHS/United States; GR: HL 070149/HL/NHLBI NIH HHS/United States; JID: 9502500; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
P. Andersen, and N. Keiding. Statistics in medicine, 31 (11-12):
1074-88(May 2012)6439<m:linebreak></m:linebreak>CI: Copyright (c) 2011; JID: 8215016; aheadofprint;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.